EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Multizentrische StudieOpen Access

Lutikizumab in Adults With Moderate to Severe Hidradenitis Suppurativa After Anti-TNF Therapy Failure

Alexa B Kimball, Konrad T Sawicki, Lindsay Ackerman, Hermenio Lima, Evangelos J Giamarellos-Bourboulis, Tianyu Zhan, Leonidas Drogaris, Yihua Gu, Christine M Lee, Mona Akbari, David A Williams, Falk G Bechara

JAMA Dermatology · 2026

DOI: 10.1001/jamadermatol.2026.0155 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JAMA Dermatology, 2026. Verfasst von Alexa B Kimball und 11 weiteren Autor:innen. Beteiligte Einrichtung: Harvard Medical School and Clinical Laboratory for Epidemiology and Applied Research in Skin, Department of Dermatology, Beth Israel Deaconess Medica…. Hauptthemen laut MEDLINE: Hidradenitis Suppurativa, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Hidradenitis suppurativa (HS) is a debilitating inflammatory skin disease with limited therapeutic options.

Objective

To assess the efficacy and safety of lutikizumab, a dual-variable domain interleukin 1α/1β antagonist, for adult participants with moderate to severe HS who experienced anti–tumor necrosis factor (TNF) therapy failure. Design, Setting, and Participants This phase 2, double-blind, placebo-controlled randomized clinical trial was conducted at 45 sites in 8 countries or territories (Australia, Canada, Germany, Greece, Japan, Puerto Rico, Spain, and the US) between December 28, 2021, and November 27, 2023, and included a 35-day screening period, a 16-week treatment period, and a 9-week safety follow-up. Data were analyzed in December 2023.

Participants

18 years or older with a diagnosis of HS for 12 months or longer who experienced anti-TNF treatment failure were enrolled.

Interventions

Eligible participants were randomized 1:1:1:1 to receive lutikizumab, 300 mg, every week; lutikizumab, 300 mg, every other week; lutikizumab, 100 mg, every other week; or placebo, every week. The trial drug was administered starting at baseline and through week 16. Main Outcomes and Measures The primary end point was achieving a Hidradenitis Suppurativa Clinical Response (HiSCR 50) at week 16. The secondary efficacy objective was achieving at least a 30% reduction and at least 1-unit reduction from baseline in Patient's Global Assessment of skin pain (Numerical Rating Scale [NRS] 30) after 16 weeks of treatment among among patients with a baseline NRS 3 or greater. Additional end points included achieving HiSCR 75 and HiSCR 90, change and percentage change from baseline in draining tunnels, and change from baseline in Dermatology Life Quality Index total scores.

Results

A total of 153 participants received at least 1 dose of the trial medication (94 female individuals [61.4%]; mean [range] age, 40.5 [19-75] years; 108 patients [70.6%] at Hurley stage III). At week 16, 19 (48.7%), 22 (59.5%), and 10 participants (27.0%) receiving lutikizumab, 300 mg, every week; lutikizumab, 300 mg, every other week; and lutikizumab, 100 mg, every other week, respectively, achieved HiSCR50 at week 16 compared with placebo (35.0%); posterior probabilities of positive treatment effect vs placebo were 89.3%, 98.5%, and 22.8%, respectively, using a bayesian analysis. Among participants with baseline NRS scores of 3 or greater, 10 (34.5%) who received lutikizumab, 300 mg, every other week and 8 (34.8%) who received lutikizumab, 300 mg, every week achieved an NRS30 response compared with 4 (12.9%) who received placebo. There were no deaths or treatment-emergent adverse events of neutropenia, serious hypersensitivity reactions, major adverse cardiovascular events, or opportunistic infections reported. Conclusions and Relevance In this phase 2 randomized clinical trial, lutikizumab, 300 mg, every week and 300 mg every other week showed positive treatment effects vs placebo in a hard-to-treat moderate to severe HS population that experienced anti-TNF therapy failure. Trial Registration ClinicalTrials.gov Identifier: NCT05139602

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hidradenitis SuppurativaAntibodies, Monoclonal, HumanizedHumansFemaleAdultDouble-Blind MethodMaleMiddle AgedSeverity of Illness IndexTreatment FailureTumor Necrosis Factor-alphaTreatment Outcome

Substanzen

Tumor Necrosis Factor-alphaAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Harvard Medical School and Clinical Laboratory for Epidemiology and Applied Research in Skin, Department of Dermatology, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
  • AbbVie Inc, North Chicago, Illinois.
  • Medical Dermatology Specialists, US Dermatology Partners, University of Arizona College of Medicine, Phoenix.
  • LEADER Research, Medicine Department Division of Clinical Immunology and Allergy, Division of Dermatology, McMaster University, Hamilton, Ontario, Canada.
  • Fourth Department of Internal Medicine, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
  • International Center for Hidradenitis Suppurativa/Acne Inversa, Department of Dermatology, Venereology and Allergology, Ruhr-University Bochum, Bochum, Germany.

Zitieren

APA

Kimball, A. B., Sawicki, K. T., Ackerman, L., Lima, H., Giamarellos-Bourboulis, E. J., Zhan, T., Drogaris, L., Gu, Y., Lee, C. M., Akbari, M., Williams, D. A., & Bechara, F. G. (2026). Lutikizumab in Adults With Moderate to Severe Hidradenitis Suppurativa After Anti-TNF Therapy Failure. JAMA Dermatology. https://doi.org/10.1001/jamadermatol.2026.0155

Vancouver

Kimball AB, Sawicki KT, Ackerman L, Lima H, Giamarellos-Bourboulis EJ, Zhan T, et al. Lutikizumab in Adults With Moderate to Severe Hidradenitis Suppurativa After Anti-TNF Therapy Failure. JAMA Dermatology. 2026. doi:10.1001/jamadermatol.2026.0155

BibTeX
@article{Kimball2026,
  author = {Kimball, Alexa B and Sawicki, Konrad T and Ackerman, Lindsay and Lima, Hermenio and Giamarellos-Bourboulis, Evangelos J and Zhan, Tianyu and Drogaris, Leonidas and Gu, Yihua and Lee, Christine M and Akbari, Mona and Williams, David A and Bechara, Falk G},
  title = {Lutikizumab in Adults With Moderate to Severe Hidradenitis Suppurativa After Anti-TNF Therapy Failure},
  journal = {JAMA Dermatology},
  year = {2026},
  doi = {10.1001/jamadermatol.2026.0155}
}
Kostenlos starten →